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Abstract: Tuberculosis (TB) is a dreadful bacterial disease, infecting millions of human and cattle
every year worldwide. More than 50 years after its discovery, ethambutol continues to be an effective
part of the World Health Organization’s recommended frontline chemotherapy against TB. However,
the lengthy treatment regimens consisting of a cocktail of antibiotics affect patient compliance.
There is an urgent need to improve the current therapy so as to reduce treatment duration and
dosing frequency. In this study, we have designed a novel anti-TB multifunctional formulation by
fabricating graphene oxide with iron oxide magnetite nanoparticles serving as a nano-carrier on to
which ethambutol was successfully loaded. The designed nanoformulation was characterised using
various analytical techniques. The release of ethambutol from anti-TB multifunctional nanoparticles
formulation was found to be sustained over a significantly longer period of time in phosphate buffer
saline solution at two physiological pH (7.4 and 4.8). Furthermore, the nano-formulation showed
potent anti-tubercular activity while remaining non-toxic to the eukaryotic cells tested. The results
of this in vitro evaluation of the newly designed nano-formulation endorse its further development
in vivo.
Keywords: Multifunctional nanocarrier; nanoformulation; ambutol; graphene oxide; iron oxide
magnetite; tuberculosis
1. Introduction
Tuberculosis (TB) is an infectious, bacterial disease caused by Mycobacterium tuberculosis (MTB)
and it is a global health and economic concern, especially in the developing world [1,2]. On an
average, it infects over 10 million people annually and kills over a million. Frontline chemotherapy
Molecules 2017, 22, 1697; doi:10.3390/molecules22101697 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1697 2 of 13
for the treatment of drug-sensitive forms of the disease is a standardised six-month regimen of a
cocktail of antibiotics, including the cell wall inhibitor-ethambutol (ETB). However, the protracted
treatment regimen needed for frequent dosing and the hepatotoxicity caused as a result of the treatment
complicates patient compliance, exacerbating the rising antimicrobial resistance crisis in TB.
Potentiating current therapy by altering the delivery and administration routes of these drugs is
garnering attention in the international scientific communities. Nanomedicine is a rapidly advancing
field in biomedical science where nanomaterials are designed and applied for theranostic (therapeutic
and diagnosis) applications [3–5]. Multifunctional nanoparticles that combine physico-chemical
properties of different nanomaterials resulting in improved characteristics are highly sought after
as drug delivery systems [6]. Recently, a variety of nanomaterials-based antimicrobials agents have
been developed [1,7–9]. Graphene oxide (GO) is a promising material for biomedical applications,
especially in drug delivery systems because of its two dimensional (2D) nanosize providing a large
surface area with different functional groups, such as hydroxyl, carbonyl, epoxides, and unsaturated
benzene rings [10,11]. These functional groups allow different drugs, hydrophilic and hydrophobic,
to be loaded on GO. Oxygenated functional groups enable drug loading via hydrogen bonding,
electrostatic interaction, and unsaturated benzene rings help loading hydrophobic drugs via pi-pi
interactions [10,12–17]. GO is getting increased attention for its applications in the design of new
antibacterial therapy because of its tendency to induce oxidative stress by generating reactive oxygen
species (ROS) and lipid peroxidation of the bacterial cell envelope [12]. GO disrupts bacterial
physiological activity, its cell-wall and GO nano-sheets can trap bacteria better than graphene because of
their oxygenated functional groups [12,18–20]. Because of the fascinating characteristics of GO, such as
the ease of hydrophobic and hydrophilic drug loading, scalable preparation, better water dispersibility,
sustained release, and its antibacterial properties make it an ideal candidate for drug delivery
applications. Meanwhile, iron oxide magnetite nanoparticles (FeNPs) possess excellent, tailored
surface properties, strong magnetic character and high biocompatibility, making them suitable for
biomedical applications [4,21]. FeNPs have been widely applied in magnetic resonance imaging (MRI),
hyperthermia, drug delivery, tissue repair, topical applications, bio-sensing, and bioanalysis [15,22–26].
Multifunctional nanoparticles based on GO and FeNPs are becoming increasingly popular as drug
delivery agents because of their additive hyperthermia effect [27]. In this study, we have designed
multifunctional nanoparticles formulation (nano-formulation) by fabricating graphene oxide with
iron oxide magnetite nanoparticles (FeNPs-GO) loaded with the front-line anti-tubercular drug,
ethambutol, resulting in anti-TB multifunctional nanoformulation (ETB-FeNPs-GO). The designed
nano-formulation was characterized in detail using various analytical techniques and evaluated for
biocompatibility and therapeutic efficacy.
2. Results
2.1. Physico-Chemical Characterization
2.1.1. Powder X-ray Diffraction (XRD) of ETB-FeNPs-GO
Figure 1a shows the x-ray diffraction (XRD) patterns of FeNPs, GO, free drug ETB and anti-TB
multifunctional nanoformulation (ETB-FeNPs-GO). The FeNPs alone show five characteristic peaks
because of (220), (311), (400), (422) and (511) planes at 2θ = 30.3◦, 35.7◦, 43.4◦, 53.6◦ and 57.3◦,
respectively. These five peaks are an exact match to pure iron oxide magnetite nanoparticles showing a
high purity of the designed FeNPs having cubic inverse spinel structure [28]. The free drug ETB showed
three crystalline intense peaks at 2θ of 7.86◦, 15.48◦ and 23.25◦ due to the crystalline characteristics of
organic molecule [14]. GO showed a characteristic peak at about 2θ = 10.0◦ due to the (001) planes
and no peak is observed due to starting material graphite which usually appears at 2θ = 26.27◦ and
the absence of graphite peaks indicates the high purity of GO [29]. The anti-TB multifunctional
nanoformulation (ETB-FeNPs-GO) showed a diffraction peak at 2θ = 10.0◦ due to the (001) planes of
GO as well as the characteristic peaks of FeNPs due to (220), (311), (400), (422) and (511) planes at
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2θ = 30.3◦, 35.7◦, 43.4◦, 53.6◦ and 57.3◦, respectively. The presence of these five characteristic peaks of
iron oxide magnetite nanoparticles and typical peak of GO at about 2θ = 10.0◦ in the multifunctional
nanoformulation (ETB-FeNPs-GO) confirms the successful formation. The drug ETB did not show any
peak in the ETB-FeNPs-GO, which is a common phenomenon that has been reported previously [24,30].
The presence of ETB loading on FeNPs-GO was confirmed by other complimentary techniques like
FTIR, HPLC, and UV/Vis spectroscopy discussed in detail in the later sections.
2.1.2. Fourier Transformed Infrared (FTIR) Spectroscopic Analysis
Figure 1b represents the FTIR spectra of free drug ETB, FeNPs, GO, and anti-TB multifunctional
nanoformulation (ETB-FeNPs-GO). The free drug ETB showed characteristic absorption bands of its
functional groups, namely stretching bands for N-H, O-H, C-H, C-N, and C-O at 3739 cm−1, 3419 cm−1,
2975 cm−1, 2809 cm−1, and 1060 cm−1, respectively [31,32]. The iron oxide magnetite nanoparticles
showed typical peaks of O-H, F-O stretching bands at 3419 cm−1 and 572 cm−1, respectively [24].
Different functional groups, bands peaks associated with GO such as O-H, carbonyl (C=O), C=C,
alkoxy and epoxides groups were observed at 3429 cm−1, 1722 cm−1, 1629 cm−1 and 1064 cm−1,
respectively [14,29,33]. The anti-TB multifunctional nanoformulation showed the functional groups
bands of ETB, FeNPs, and GO with slight shifts. The presence of bands belonging to the functional
group of ETB, FeNPs, and GO indicate successful formation anti-TB multifunctional nanoformulation
(ETB-FeNPs-GO). Table 1 shows the assignment of each individual band of the sample.
Table 1. FTIR assignments of absorption bands of free ETB, GO, FeNPs, and multifunctional
nanoformulation (ETB-FeNPs-GO).
Assignments Free ETB FeNPs GO ETB-FeNPsGO
N-H Stretching 3739 cm−1 - - 3730 cm−1
O-H Stretching 3419 cm−1 3419 cm−1 3429 cm−1 3431 cm−1
C-H Stretching 2975 cm−1 - 2975 & 2809 cm−1 2924 cm−1
C=O, C=C stretching - - 1722 & 1629 cm−1 1630 cm−1
C-N Stretching 1315 cm−1 - - 1384 cm−1
C-O Stretching 1060 cm−1 1034 cm−1 ~1064 cm−1 1051 cm−1
F-O stretching - 575 cm−1 - 583 cm−1
Abbreviations in Table 1: ETB (Ethambutol), FeNPs (iron oxide magnetite nanoparticles), anti-TB multifunctional
nanoformulation (ETB-FeNPs-GO).
2.1.3. Raman Spectroscopy Analysis
Raman spectroscopy is a useful technique for the analysis of defects, disorder, and changes in
the structure of carbon based material due to chemical modifications/reactions [34]. Figure 1c shows
the Raman spectra of GO and ETB-FeNPs-GO. In the Raman spectrum of GO, two peaks, D and G,
were observed due to the characteristics graphitic nature. The D band is due to the disorder-induced
mode, and the G-band is due to the graphitic-like mode that appeared at 1349 and 1557 cm−1,
respectively [35–37]. The presence of the D and G bands in the multifunctional nanoformulation
with almost similar intensity, as shown by GO Raman bands, indicates the presence of GO in the
ETB-FeNPs-GO. The ratio of ID over IG for GO alone and ETB-FeNPs-GO was found to be 1.0 when
compared to the graphite intensity ratio of ID/IG = 0.833, which is in agreement with previous
studies [35].
2.1.4. HPLC and ICP Analysis
The quantification of iron (Fe) content and ETB loading was determined using inductively coupled
plasma (ICP) and high performance liquid chromatography (HPLC) analysis, respectively. For iron
content quantification, various standards of Fe i.e., 25 ppm, 50 ppm, 100 ppm, 200 ppm, and 250 ppm
were analysed by ICP, the calibration curve was plotted, and r2 was found to be 0.9987. The amount of
iron (Fe) in the multifunctional nanoformulation ETB-FeNPs-GO was found to be 62.30% (1.11 moles).
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The drug (ETB) loading in the designed multifunctional nanoformulation (ETB-FENPs-GO) was
determined by HPLC analysis. For the calibration curve, different standard concentrations of ETB
were prepared e.g., 25 ppm, 50 ppm, 100 ppm, 150 ppm, 200 ppm, and r2 was determined to be 0.9980
(graph of calibration curve is given in Supplementary Material Figure S1). The loading of the ETB
in anti-TB multifunctional nanoformulation (ETB-FeNPs-GO) was found to be 33.83% (0.166 moles).
The empirical formula of the designed anti-TB multifunctional nanoformulation (ETB-FeNPs-GO) was
determined to be [(C10H24N2O2)0.166 (Fe3O4)1.11 (GO)(x)].
2.1.5. Transmission Electron Microscopic (TEM) Analysis
Figure 1d (A–D) shows the transmission electron micrographs of multifunctional nanocarrier
alone FeNPs-GO (A), its particle size distribution of FeNPs-GO (B), the anti-TB multifunctional
nanoformulation ETB-FeNPs-GO (C), and its particle size distribution of ETB-FeNPs-GO (D),
respectively. The shape of multifunctional nanocarrier FeNPs-GO was found to be roughly circular.
The particle size distribution was measured using image processing software (UTHSCSA Image Tool
for Windows Version 3.00) by randomly selecting 104 particles (N), and it was determined to be of
27.76 nm ± 4.458 nm. The shape of ETB-FeNPs-GO was also found to be roughly circular with the
particles being agglomerated. The particle size of the ETB-FeNPs-GO was determined by randomly
selecting 134 particles (N), and it was found to be 9.09 nm ± 1.627 nm. The small particle size of the
ETB-FeNPs-GO compared to empty carrier FeNPs-GO may possibly be attributed to the extra stirring
during the drug loading process and the smaller size of drug loaded when compared to the empty
carrier has also been reported previously [20,38].
2.2. Magnetic Properties
Magnetic properties of the FeNPs and of the ETB-FeNPs-GO were analysed using Vibrating
Sample Magnetometry (VSM) analysis. Figure 1e shows the VSM hysteresis loops as a function
of the magnetic field at room temperature. For iron oxide magnetite nanoparticles, saturation
magnetization (Ms) was determined to be 31.36 emu/g with a remnant magnetization (Mr) of
0.78 emu/g. For anti-TB multifunctional nanoformulation, ETB-FeNPs-GO saturation magnetization
was found to be 19.02 emu/g with remnant magnetization (Mr) 0.70 emu/g. The VSM analysis
data revealed that both samples possess superparamagnetic behaviour because the samples did
not show any magnetism in the absence of magnetic field. The superparamagnetic nature of the
multifunctional nanoformulation (ETB-FeNPs-GO) makes it more suitable for the target delivery
drug and other biomedical application with additive hyperthermia properties. These magnetic
nanoparticles have the tendency to get hotter when external magnetic field is applied and have
been used in killing/eradication bacteria and cancerous cells by the hot FeNPs, called killing by
magnetic hyperthermia [39,40].
2.2.1. In vitro Drug Release Study
Figure 1f shows the in vitro release profile of ETB from anti-TB multifunctional nanoformulation
in phosphate buffered saline (PBS) solution of pH 7.4 (A) and in PBS solution of pH 4.8 (B). Under
both conditions of the PBS solution, the initial (~40%) releases were relatively faster when compared
to the later 60% release. This faster release can be attributed to the less tightly bonded/adsorbed
drug molecules within multifunctional nanocarrier FeNPs-GO and the later stage, sustained release
can be attributed to the tightly bound drug molecules. The total time for 100% release of the drug
was determined to be about 3000 min (50 h) under both conditions. The free drug ETB under similar
conditions took 10 min for 100% release, as we have previously reported [41]. This suggests that
multifunctional nanoparticles formulation ETB-FeNPs-GO sustained the release for much longer time
when compared to free drug ETB. This sustained release characteristic has implications in improving
the bioavailability of the drug.
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Figure 1. (a) X-ray diffraction patterns of iron oxide magnetite nanoparticles (FeNPs), free drug 
ethambutol (ETB), graphene oxide (GO), and anti-TB multifunctional nanoformulation 
(ETB-FeNPs-GO) (b) FTIR spectra of ETB, FeNPs, GO, and of ETB-FeNPs-GO; (c) Raman spectra of 
GO (A) and anti-TB multifunctional nanoformulation formulation ETB-FeNPs-GO (B); (d) 
Transmission electron micrograph (TEM) of FeNPs-GO (A) and their particle size distribution (B), 
TEM of anti-TB multifunctional nanoformulation (C) and their particles size distribution (D); (e) 
Magnetization plots of FeNP alone and multifunctional nanoformulation ETB-FeNPs-GO; (f) In vitro 
Figure 1. (a) X-ray diffraction patterns of iron oxide magnetite nanoparticles (FeNPs), free
drug ethambutol (ETB), graphene oxide (GO), and anti-TB multifunctional nanoformulation
(ETB-FeNPs-GO) (b) FTIR spectra of ETB, FeNPs, GO, and of ETB-FeNPs-GO; (c) Raman spectra of GO
(A) and anti-TB multifunctional nanoformulation formulation ETB-FeNPs-GO (B); (d) Transmission
electron micrograph (TEM) of FeNPs-GO (A) and their particle size distribution (B), TEM of anti-TB
multifunctional nanoformulation (C) and their particles size distribution (D); (e) Magnetization plots
of FeNP alone and multifunctional nanoformulation ETB-FeNPs-GO; (f) In vitro release profile of
Ethambutol (ETB) from anti-TB multifunctional nanoformulation (ETB-FeNPs-GO) in PBS solutions of
pH 7.4 (A) and pH 4.8 (B).
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2.2.2. Nano-Formulation Shows Antimycobacterial Activity
Minimum inhibitory concentrations (MIC) of free drug ETB and ETB-FeNPs-GO was determined
against M. smegmatis using REMA and modified SPOTi assay, as shown in Table 2 and Figure 2a.
The loading percentage of ETB on FeNPs-GO as determined by HPLC is 33.83%. Taking this into
account, the effective MIC of ETB-FeNPs-GO is 2.1 µg/mL.
Table 2. The minimum inhibitory concentration of the compounds tested based on the liquid culture
Resazurin Microtiter Assay (REMA) assay with M. smegmatis.
Compound
REMA Modified SPOTi
Observed MIC
(µg/mL)
Effective MIC
(µg/mL)
Observed MIC
(µg/mL)
Effective MIC
(µg/mL)
ETB 0.39 0.39 0.39 0.39
ETB-FeNPs-GO 6.25 2.1 6.25 2.1
2.2.3. Biofilm Inhibition by ETB-FeNPs-GO
ETB-FeNPs-GO was found to inhibit the formation of a continuous biofilm at the air-liquid
interface at the MIC for planktonic cells (effective concentration 2.1 µg/mL). Complete inhibition of
all cell growth is seen at a concentration that is two-fold higher than the MIC (effective concentration
2.1 µg/mL). ETB alone inhibits biofilm formation in M. smegmatis at its MIC of 0.39 µg/mL, apparently,
resulting in better inhibition in vitro than the nanoformulation (shown in Figure 2b,c) reasonably, due
to the sustained release of the drug.
2.2.4. Cytotoxicity Studies
In vitro cytoxicity profile of free drug ETB, nanocarrier FeNPs-GO, and multifunctional
nanoformulation (ETB-FeNPs-GO) was evaluated on eukaryotic 3T3 cells using a range of
concentrations (i.e., 0.78–50 ug/mL) of all the samples. Untreated cells were taken as standard.
Cells were incubated with the samples for 72 h and cell viability was determined using MTT assay. All
of the samples were found to be highly biocompatible as the cell viability was found to be more than
80% after 72 h treatment period as shown in Figure 2d.
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Figure 2. (a) REMA and SPOTi results based on ETBambutol (ETB) and multifunctional
nanoformulation ETB-FeNPs-GO, tested on M. smegmatis; (b) Complete biofilm inhibition in 96 well
plate results based on ETB and ETB-FeNPs-GO tested on M. smegmatis according to their MIC; (c) Crystal
violet quantification of concentration-dependent inhibition of biofilmsby ETB and ETB-FeNPs-GO;
(d) Cell viability determined using MTT for the ETB, FeNPs-GO, and ETB-FeNPs-GO.
3. Discussion
Here, we report the design of a multifunctional anti-tuberculosis nanoformulation by the
fabrication of iron oxide magnetite (FeNPs) and graphe e oxide. The first line anti-TB dr g, ethambutol,
was successfully loaded onto the designed multifunctional nanocarrier (FeNPs-GO). Release studies
conducted in human body-simulated PBS solution of human blood pH 7.4 a d intracellular lysosomal
pH 4.8 fo nd the sustained release of up to 50 h when compared t free drug ETB, which took
10 min for 100% release under similar conditions. The prolonged sustai ed release property of
designed formulation has the potential to reduce the dosi g frequency for treatment. Additionally,
multifunctional anti-TB nanoformulation (ETB-FeNPs-GO) was foun to be highly biocompatible with
cell viabilit of about 90% when 3T3 fibroblast cells were exposed to 50 µg/mL of the formulation
for up to 72 h. The anti-mycobacterial activity of ETB in the formulation is lower than that of the free
drug. However, incubation periods of 24 h would not have been enough to release the entire drug-load
bound to the nanoformulation. The designed formulation sh ws potent antimycobacterial activity, and
most importantly, was f und to maintain its superparamagnetic character. The superparamagn tic
nature can be further investigated f r its a plication in the hyperther ic killi g of pathogenic bacteria.
We beli ve t is work to be a step forward in making the chemother py of TB patient-friendly with
enhanced bioavailability nd therapeutic effects achieved through reduced dosing frequency.
4. Materials and Methods
4.1. Materials
Pure drug Ethambutol dihydrochloride (99% purity), hydrogen peroxide (H2O2), potassium
permanganate (KMnO4), sulfuric acid (H2SO4, 98%), graphite flakes with 109 meshes,
phosphate-buffered saline, and phosphoric acid (H3PO4), were purchased from Sigma Aldrich
(St. Louis, MO, USA) and were used without further purification. Sodium hydroxide, diethyl ether,
and hydrochloric acid (HCl, 37%) were purchased from Friedemann Schmidt (Parkwood, WA, USA).
The 3T3 fibroblast cell lines were purchased from the American Tissue Culture Collection (Manassas,
VA, USA) and deionized water was used in all experiments.
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4.2. Instrumentations
Shimadzu XRD-6000 Diffractometer (Shimadzu Corporation, Tokyo, Japan) was used for X-ray
diffraction (XRD) studies with CuKα radiation at 30 kV and 30 mA. A Perkin-Elmer 100 series
spectrophotometer Fourier transform infrared (FTIR) (Waltham, MA, USA) was applied for the
functional group analysis and spectra were recorded by the direct sample method. For the optical and
in vitro release studies a Perkin Elmer Lambda 35 ultraviolet-visible spectrophotometer (Waltham, MA,
USA) was used. The Raman spectra were recorded with excitation wavelength (598 nm) using Raman
spectrometer Witec Model: Alpha 300R (Witec, Ulm, Germany). The drug loading was quantified
using Sykam high performance liquid chromatography (HPLC) system (SYKAM GmbH, Eresing,
Germany) was used with the a Sykam S3250 UV/Vis detector auto injector Sykam 5300, and the Sykam
quaternary pump system 5300 made in Germany, with a Zorbax Rx-Sil column of 4.6 × 150 mm, with
5 µm particle size (Agilent Technologies, Santa Clara, CA, USA).
4.3. Synthesis of Graphene Oxide
Graphene oxide was synthesized via oxidative exfoliation by an improved method [29]. In short,
concentrated H2SO4 (360 mL) and concentrated H3PO4 (40 mL) were added to a mixture of graphite
powder (3 g) and KMnO4 (18 g), and the solution was kept on stirring under constant heating at
50 ◦C for 12 h. The sample was cooled down to room temperature and poured onto cubes of ice
(400 g) containing 3 mL of hydrogen peroxide (H2O2). Synthesized GO was subjected to work up by
successive washing with water (200 mL), hydrochloric acid (HCl) (200 mL), ethanol (200 mL), followed
coagulation with diethyl ether (200 mL), and the final product was dried in an oven at 40 ◦C [29].
4.4. Synthesis of Iron Oxide Magnetite Nanoparticles Fe3O4 (FeNPs)
Iron oxide magnetite nanoparticles were synthesized using the previously reported method [24].
In short, in 80 mL aqueous solution of Ferric chloride hexahydrate (FeCl3·6H2O) 0.99 g plus Ferrous
chloride tetra hydrate (FeCl2·4H2O) (2.43 g), and a few drops of 5 M NaOH solution were added under
vigorous stirring till the pH rose to 11 and black precipitates were formed. The synthesized product
was subjected to ultra-sonication for an hour (at ultrasonic irradiation of 20 kHz), and then subjected to
work up with thorough washing by deionized water, dried in oven for 24 h at 70 ◦C, and the product
was ground to powder [24].
4.5. Synthesis of Multifunctional Nanoparticles FeNPs-GO and Loading of Ethambutol (ETB)
The iron oxide magnetite nanoparticles (FeNPs) product was added to 50 mL of 1% GO aqueous
solution and the sample was stirred for 24 h at room temperature. The obtained product was washed,
centrifuged, and dried at 40 ◦C, and was ground to powder. For drug loading, 0.25 g of multifunctional
nanoparticles (FeNPs-GO) were added to 1% aqueous solution of ETB followed by 24 h stirring.
After that, the sample was washed with water followed by centrifugation, dried in an oven at 40 ◦C
and the resulting sample contained anti-TB multifunctional nanoparticles nanoformulation (referred
to as nano-formulation in rest of the manuscript).
4.6. Sustained Release of Nano-Formulation In Vitro
In vitro release of ETB from the nanoformulation was monitored in phosphate buffer saline (PBS),
simulating human blood (pH 7.4) and lysosomal (pH 4.8) conditions. Approximately 4 mg of the
ETB-FeNPs-GO nano-formulation was placed in 3.5 mL of each PBS solution separately and release
behaviour of ETB was recorded using UV/Vis spectrophotometer using lambda max of ETB 192 nm.
4.7. High Performance Liquid Chromatography (HPLC) Analysis for ETB Loading
HPLC analysis was performed for drug loading quantification of the ETB in designed
nano-formulation (ETB-FeNPs-GO) using previous method [42]. In short, the solvent system used was
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acetonitrile (solvent A) and 15 mmol/L potassium dihydrogen phosphate buffer with pH adjusted
to 4.0 ± 0.1 (solvent B). The solvent systems were made in the ratio of 89:11 (A:B) with a flow rate of
1 mL/min at 25 ◦C and UV detector was used with set wavelength of 190 nm. For calibration curve
different standard concentrations of ETB i.e., 25 ppm, 50 ppm, 100 ppm, 150 ppm, and 200 ppm were
analyzed by HPLC and r2 was found to be 0.9980. The multifunctional nanoformulation 10 mg was
put in 10 mL of 1 molar of PBS buffer and sonicated for 1 h and sample was kept in the same buffer
for 15 days to ensure 100% percent release of the drug. After that, the sample was filtered using 2 µL
filter and then transferred to the HPLC injection vial for HPLC analysis, and three different samples of
nanoformulation (ETB-FeNPs-GO) were prepared in the similar way. Samples were analyzed using
above HPLC protocol after running the ETB calibration standards. The calibration curve for the
standards is given in the Supplementary Material Figure S1.
4.8. Biological Evaluation
4.8.1. MTT Assay for In Vitro Cytotoxicity Studies
The MTT [3-(4,5-dimylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was utilized for the
cytotoxicity evaluation of the nanocarrier (FeNPs-GO), free drug ETB, and anti-TB nano-formulation
(ETB-FeNPs-GO). Cells with a density of 1.0 × 105 cells per well were seeded in 100 µL of cell culture
medium. After one day of the cells incubation, cells were treated with all the above samples various
(0.78 to 50 µg/mL) in triplicates and incubated for 72 h. After 72 h, the MTT solution concentration
of 5 mg/mL was added to each well then incubated further for 4 h. After 4 h 100 µL of dimethyl
sulfoxide was added to each well for the dissolution of dark blue formazan crystals resulted by the
reduction of tetrazolium by living cells. The living cells were quantified by microplate enzyme-linked
immunosorbent assay reader (ELx800, BioTek Instruments, Winooski, VT, USA) choosing wavelength
of 570 nm and 630 nm [43]. Cell viability data presented in the percentage values are in comparison to
the untreated cells (standard) under the same experimental conditions. The experiments were carried
out in triplicate for each sample and results are presented with mean ± standard deviation.
4.8.2. Resazurin Microtiter Assay (REMA)
The minimum inhibitory concentration (MIC) was established by the drug susceptibility assay
Resazurin Microtiter Assay (REMA) [44]. In brief, 2 µL of the initial drug/nanoformulation stock of
concentration 100 µg/mL was added to 198 µL of media in a microtiter plate, and 100 µL of this was
used to serially dilute (two-fold) the drug along the columns of the plate. Mycobacterial culture was
grown until early-logarithmic phase (OD600~1.00) and 100 µL of 10−3 dilution of the cell suspension
was added to each well [45]. M. smegmatis was incubated with the compounds for 24 h at 37 ◦C. Solvent
(DMSO), carrier (FeNPs-GO), drug-free, and cell-free controls were set up. After incubation, 30 µL of
resazurin dye mixture (1:1 (v/v) of 0.01% (w/v) resazurin and 20% (v/v) Tween-80%) was added to
each well and was incubated for a further 6–9 h. A change from blue to pink indicates the growth of
bacteria. The MIC was determined by the lowest concentration of the compound that prevents the
colour change. The experiment was performed in triplicate.
4.8.3. Modified SPOTi Assay
This assay is based on SPOTi assay [46–49]. M. smegmatis cells were grown (37 ◦C, 180 rpm) to
logarithmic growth phase (OD600~1.00) and 100 µL of 10−3 dilution of the bacterial cell suspension
(1 × 105 CFU) was incubated with a range of serially diluted concentrations of the drug and its
nanoformulations (25–0.1 µg/mL) in a 96 well microtitre plate. Solvent (DMSO), carrier (FeNPs-GO),
drug-free and bacilli-free controls were set up. The plate was incubated for 24 h at 37 ◦C, shaking at
150 rpm for maintaining a uniform suspension of cells and the formulation in solution. After the end
of incubation, 2 µL of the cell suspension was spotted onto microtiter plate with each well containing
200 µL of M7H10 media (BD Biosciences, Swindon, UK) supplemented with 0.02% (v/v) glycerol and
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10% Oleic acid-Albumin-Dextrose-Catalase (OADC, BD Biosciences, UK). The plate was incubated at
37 ◦C for three days until visible spots of bacterial growth appeared in the wells inoculated with cell
suspension from the drug-free controls. The experiment was performed in triplicate.
4.8.4. Biofilm Inhibition Assay
Biofilm growth and inhibition assay was prepared in 96 well plates (Corning, polystyrene,
non-treated) [50]. M. smegmatis cells were grown to late-logarithmic phase (OD600 ~4) and 10 µL
of the cell culture was added to each well containing up to 200 µL of Sauton’s media (0.5 g KH2PO4,
0.5 g MgSO4, 4.0 g L-asparagine, 0.05 g ferric ammonium citrate, 2.0 g citric acid, 60 mL glycerol
dissolved in 900 mL dH2O and pH adjusted to 7) containing the drug or formulation in a range of
concentrations between 25–0.19 µg/mL. Solvent (DMSO), carrier (FeGO), drug-free, and cell-free
controls were set up. The plates were left in the incubator for five days at 37 ◦C, static conditions. After
the given incubation time, the media containing planktonic cells was aspirated and the plate was left
in a hot oven at 50 ◦C for 10 min to allow for the biofilm to dry. Crystal violet (0.1% v/v) was added
to each well and left to incubate for 30 min at room temperature. Lastly, 30% acetic acid was added
to solubilise the biofilm for 30 min at room temperature. The content of each well was transferred to
a new 96 well plate and the OD600 was read using a plate reader Biotek (Synergy, Perth, Australia).
The experiment was carried out in triplicate. Solvent (DMSO), carrier (FeNPs-GO), drug-free, and
bacilli-free controls were set up.
Supplementary Materials: Supplementary materials are available online.
Acknowledgments: ERS Short-Term Research Training Fellowship 2016 (ID Number STRTF 2016-7461) for BS at
BIOL and UPM-MOHE Nanomite grant vot No. 9443100 is gratefully acknowledged. A.M. would like to thank
Wellcome Trust-Birkbeck Anniversary studentship for funding her Ph.D. studies. S.B. is a Cipla Distinguished
Fellow in Pharmaceutical Sciences.
Author Contributions: B.S., S.B., S.F. and M.Z.H. conceived and designed the project; B.S., B.N., A.C., A.M.
performed the experiments; B.S. and A.M. wrote the first complete draft of the manuscript. All other authors
reviewed and contributed significantly to improve the manuscript for its final submission.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Saifullah, B.; Hussein, M.Z.; Al Ali, S.H.H. Controlled-release approaches towards the chemotherapy of
tuberculosis. Int. J. Nanomed. 2012, 7, 5451–5463. [CrossRef] [PubMed]
2. Global Tuberculosis Report 2016; World Health Ognization: Geneva, Switzerland, 2016; p. 192.
3. Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and
opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [CrossRef] [PubMed]
4. Nochehdehi, A.R.; Thomas, S.; Sadri, M.; Afghahi, S.S.S.; Hadavi, S.M. Iron Oxide Biomagnetic Nanoparticles
(IO-BMNPs); Synthesis, Characterization and Biomedical Application. J. Nanomed. Nanotechnol. 2017, 8, 1–9.
5. Chen, G.; Roy, I.; Yang, C.; Prasad, P.N. Nanochemistry and Nanomedicine for Nanoparticle-based
Diagnostics and Therapy. Chem. Rev. 2016, 116, 2826–2885. [CrossRef] [PubMed]
6. Tian, T.; Shi, X.; Cheng, L.; Luo, Y.; Dong, Z.; Gong, H.; Xu, L.; Zhong, Z.; Peng, R.; Liu, Z. Graphene-based
nanocomposite as an effective, multifunctional, and recyclable antibacterial agent. ACS Appl. Mater. Interface
2014, 6, 8542–8548. [CrossRef] [PubMed]
7. Sondi, I.; Salopek-Sondi, B. Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for
Gram-negative bacteria. J. Colloid Interface Sci. 2004, 275, 177–182. [CrossRef] [PubMed]
8. Xu, L.; Wan, C.; Du, J.; Li, H.; Liu, X.; Yang, H.; Li, F. Synthesis, characterization, and in vitro evaluation
of targeted gold nanoshelled poly(d,l-lactide-co-glycolide) nanoparticles carrying anti p53 antibody as a
theranostic agent for ultrasound contrast imaging and photothermal therapy. J. Biomater. Sci. Polym. Ed.
2017, 28, 415–430. [CrossRef] [PubMed]
9. Saifullah, B.; Hussein, M.Z.B. Inorganic nanolayers: structure, preparation, and biomedical applications.
Int. J. Nanomed. 2015, 10, 5609–5633.
Molecules 2017, 22, 1697 11 of 13
10. Yan, T.; Zhang, H.; Huang, D.; Feng, S.; Fujita, M.; Gao, X.-D. Chitosan-Functionalized Graphene Oxide as a
Potential Immunoadjuvant. Nanomaterial 2017, 7, 59. [CrossRef] [PubMed]
11. Khan, M.Z.H. Graphene Oxide Modified Electrodes for Dopamine Sensing. J. Nanomater. 2017, 2017, 11.
[CrossRef]
12. Nanda, S.S.; Yi, D.K.; Kim, K. Study of antibacterial mechanism of graphene oxide using Raman spectroscopy.
Sci. Rep. 2016, 6, 28443. [CrossRef] [PubMed]
13. Muthoosamy, K.; Abubakar, I.B.; Bai, R.G.; Loh, H.-S.; Manickam, S. Exceedingly Higher co-loading
of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent
Synergistic Anticancer Treatment. Sci. Rep. 2016, 6, 32808. [CrossRef] [PubMed]
14. Dorniani, D.; Saifullah, B.; Barahuie, F.; Arulselvan, P.; Hussein, M.Z.B.; Fakurazi, S.; Twyman, L.J. Graphene
Oxide-Gallic Acid Nanodelivery System for Cancer Therapy. Nanoscale Res. Lett. 2016, 11, 491. [CrossRef]
[PubMed]
15. Urbas, K.; Aleksandrzak, M.; Jedrzejczak, M.; Rakoczy, R.; Chen, X.; Mijowska, E. Chemical and magnetic
functionalization of graphene oxide as a route to enhance its biocompatibility. Nanoscale Res. Lett. 2014, 9,
656. [CrossRef] [PubMed]
16. Kassaee, M.Z.; Motamedi, E.; Majdi, M. Magnetic Fe3O4-graphene oxide/polystyrene: Fabrication and
characterization of a promising nanocomposite. Chem. Eng. J. 2011, 172, 10. [CrossRef]
17. Barahuie, F.; Dorniani, D.; Saifullah, B.; Gothai, S.; Hussein, M.Z.; Pandurangan, A.K.; Arulselvan, P.;
Norhaizan, M.E. Sustained release of anticancer agent phytic acid from its chitosan-coated magnetic
nanoparticles for drug-delivery system. Int. J. Nanomed. 2017, 12, 2361–2372. [CrossRef] [PubMed]
18. Hu, W.; Peng, C.; Luo, W.; Lv, M.; Li, X.; Li, D.; Huang, Q.; Fan, C. Graphene-Based Antibacterial Paper.
ACS Nano 2010, 4, 4317–4323. [CrossRef] [PubMed]
19. Kotchey, G.P.; Allen, B.L.; Vedala, H.; Yanamala, N.; Kapralov, A.A.; Tyurina, Y.Y.; Klein-Seetharaman, J.;
Kagan, V.E.; Star, A. The Enzymatic Oxidation of Graphene Oxide. ACS Nano 2011, 5, 2098–2108. [CrossRef]
[PubMed]
20. Barahuie, F.; Saifullah, B.; Dorniani, D.; Fakurazi, S.; Karthivashan, G.; Hussein, M.Z.; Elfghi, F.M. Graphene
oxide as a nanocarrier for controlled release and targeted delivery of an anticancer active agent, chlorogenic
acid. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 74, 177–185. [CrossRef] [PubMed]
21. Karimzadeh, I.; Aghazadeh, M.; Doroudi, T.; Ganjali, M.R.; Kolivand, P.H. Superparamagnetic Iron Oxide
(Fe3O4) Nanoparticles Coated with PEG/PEI for Biomedical Applications: A Facile and Scalable Preparation
Route Based on the Cathodic Electrochemical Deposition Method. Adv. Phys. Chem. 2017, 2017, 7. [CrossRef]
22. Yu, M.K.; Jeong, Y.Y.; Park, J.; Park, S.; Kim, J.W.; Min, J.J.; Kim, K.; Jon, S. Drug-loaded superparamagnetic
iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. Engl. 2008,
47, 5362–5365. [CrossRef] [PubMed]
23. Mornet, S.; Vasseur, S.; Grasset, F.; Duguet, E. Magnetic nanoparticle design for medical diagnosis and
therapy. J. Mater. Chem. 2004, 14, 2161–2175. [CrossRef]
24. Dorniani, D.; Hussein, M.Z.B.; Kura, A.U.; Fakurazi, S.; Shaari, A.H.; Ahmad, Z. Sustained Release of
Prindopril Erbumine from Its Chitosan-Coated Magnetic Nanoparticles for Biomedical Applications. Int. J.
Mol. Sci. 2013, 14, 23639–23653. [CrossRef] [PubMed]
25. Mahmoudi, M.; Milani, A.S.; Stroeve, P. Synthesis, surface architecture and biological response of
superparamagnetic iron oxide nanoparticles for application in drug delivery: A review. Int. J. Biomed.
Nanosci. Nanotechnol. 2010, 1, 164–201. [CrossRef]
26. Goncalves, L.C.; Seabra, A.B.; Pelegrino, M.T.; de Araujo, D.R.; Bernardes, J.S.; Haddad, P.S.
Superparamagnetic iron oxide nanoparticles dispersed in Pluronic F127 hydrogel: Potential uses in topical
applications. RSC Adv. 2017, 7, 14496–14503. [CrossRef]
27. Ma, X.; Tao, H.; Yang, K.; Feng, L.; Cheng, L.; Shi, X.; Li, Y.; Guo, L.; Liu, Z. A functionalized graphene
oxide-iron oxide nanocomposite for magnetically targeted drug delivery, photothermal therapy, and
magnetic resonance imaging. Nano Res. 2012, 5, 199–212. [CrossRef]
28. Dorniani, D.; Hussein, M.Z.B.; Kura, A.U.; Fakurazi, S.; Shaari, A.H.; Ahmad, Z. Preparation of Fe3O4
magnetic nanoparticles coated with gallic acid for drug delivery. Int. J. Nanomed. 2012, 2012, 11. [CrossRef]
[PubMed]
29. Marcano, D.C.; Kosynkin, D.V.; Berlin, J.M.; Sinitskii, A.; Sun, Z.; Slesarev, A.; Alemany, L.B.; Lu, W.; Tour, J.M.
Improved Synthesis of Graphene Oxide. ACS Nano 2010, 4, 4806–4814. [CrossRef] [PubMed]
Molecules 2017, 22, 1697 12 of 13
30. Revia, R.A.; Zhang, M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring:
recent advances. Mater. Today 2016, 19, 157–168. [CrossRef] [PubMed]
31. Ahmad, M.I.; Ungphaiboon, S.; Srichana, T. The development of dimple-shaped chitosan carrier for
ethambutol dihydrochloride dry powder inhaler. Drug Dev. Ind. Pharm. 2015, 41, 791–800. [CrossRef]
[PubMed]
32. Annapurna, M.M.; Rao, M.E.B.; Kumar, B.V.V.R. Synthesis, Spectral Characterization and Evaluation of
Pharmacodynamic Activity of Copper and Nickel Complexes of Ethambutol Dihydrochloride. J. Chem. 2006,
3, 274–277. [CrossRef]
33. Verma, S.; Mungse, H.P.; Kumar, N.; Choudhary, S.; Jain, S.L.; Sain, B.; Khatri, O.P. Graphene
oxide: An efficient and reusable carbocatalyst for aza-Michael addition of amines to activated alkenes.
Chem. Commun. 2011, 47, 12673–12675. [CrossRef] [PubMed]
34. King, A.A.K.; Davies, B.R.; Noorbehesht, N.; Newman, P.; Church, T.L.; Harris, A.T.; Razal, J.M.; Minett, A.I.
A New Raman Metric for the Characterisation of Graphene oxide and its Derivatives. Sci. Rep. 2016, 6, 19491.
[CrossRef] [PubMed]
35. Gurunathan, S.; Han, J.W.; Kim, E.S.; Park, J.H.; Kim, J.H. Reduction of graphene oxide by resveratrol:
A novel and simple biological method for the synthesis of an effective anticancer nanotherapeutic molecule.
Int. J. Nanomed. 2015, 10, 19. [CrossRef] [PubMed]
36. Kalbac, M.; Hsieh, Y.-P.; Farhat, H.; Kavan, L.; Hofmann, M.; Kong, J.; Dresselhaus, M.S. Defects in
Individual Semiconducting Single Wall Carbon Nanotubes: Raman Spectroscopic and in Situ Raman
Spectroelectrochemical Study. Nano. Lett. 2010, 10, 4619–4626. [CrossRef] [PubMed]
37. Dresselhaus, M.S.; Jorio, A.; Hofmann, M.; Dresselhaus, G.; Saito, R. Perspectives on Carbon Nanotubes and
Graphene Raman Spectroscopy. Nano Lett. 2010, 10, 751–758. [CrossRef] [PubMed]
38. Dorniani, D.; Kura, A.U.; Hussein-Al-Ali, S.H.; Bin Hussein, M.Z.; Fakurazi, S.; Shaari, A.H.; Ahmad, Z.
In Vitro Sustained Release Study of Gallic Acid Coated with Magnetite-PEG and Magnetite-PVA for Drug
Delivery System. Sci. World J. 2014, 2014, 11. [CrossRef] [PubMed]
39. Wahajuddin, S.A. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers.
Int. J. Nanomed. 2012, 7, 3445–3471. [CrossRef] [PubMed]
40. Thomas, L.A.; Dekker, L.; Kallumadil, M.; Southern, P.; Wilson, M.; Nair, S.P.; Pankhurst, Q.A.; Parkin, I.P.
Carboxylic acid-stabilised iron oxide nanoparticles for use in magnetic hyperthermia. J. Mater. Chem. 2009,
19, 6529–6535. [CrossRef]
41. Saifullah, B.; Chrzastek, A.; Maitra, A.; Bullo, N.; Fakurazi, S. Novel Anti-Tuberculosis Nanodelivery
Formulation of Ethambutol with Graphene Oxide. Molecules 2017, in press.
42. Saifullah, B.; El Zowalaty, M.E.; Arulselvan, P.; Fakurazi, S.; Webster, T.J.; Geilich, B.M.; Hussein, M.Z.
Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double
hydroxide based nanocomposites. Int. J. Nanomed. 2016, 2016, 13.
43. Ahmadian, S.; Barar, J.; Saei, A.A.; Fakhree, M.A.A.; Omidi, Y. Cellular Toxicity of Nanogenomedicine in
MCF-7 Cell Line: MTT assay. JOVE J. Vis. Exp. 2009, 1191. [CrossRef] [PubMed]
44. Taneja, N.K.; Tyagi, J.S. Resazurin reduction assays for screening of anti-tubercular compounds against
dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium
smegmatis. J. Antimicrob. Chemoth. 2007, 60, 288–293. [CrossRef] [PubMed]
45. Parish, T.; Brown, A.C. Mycobacteria Protocols, 2nd ed.; Springer: Berlin, Germany, 1998.
46. Danquah, C.A.; Maitra, A.; Gibbons, S.; Faull, J.; Bhakta, S. HT-SPOTi: A Rapid Drug Susceptibility Test
(DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery.
Curr. Protoc. Microbiol. 2016, 17.8.1–17.8.12.
47. Rizi, K.; Murdan, S.; Danquah, C.A.; Faull, J.; Bhakta, S. Development of a rapid, reliable and quantitative
method—“SPOTi” for testing antifungal efficacy. J. Microbiol. Meth. 2015, 117, 36–40. [CrossRef] [PubMed]
48. Guzman, J.D.; Evangelopoulos, D.; Gupta, A.; Birchall, K.; Mwaigwisya, S.; Saxty, B.; McHugh, T.D.;
Gibbons, S.; Malkinson, J.; Bhakta, S. Antitubercular specific activity of ibuprofen and the other
2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3, e002672.
[CrossRef] [PubMed]
49. Evangelopoulos, D.; Bhakta, S. Rapid methods for testing inhibitors of mycobacterial growth. In Antibiotic
Resistance Protocols, 2nd ed.; Gillespie, S.H., McHugh, T.D., Eds.; Springer: Berlin, Germany, 2010; Volume 642,
pp. 193–201.
Molecules 2017, 22, 1697 13 of 13
50. O’Toole, G.A. Microtiter dish biofilm formation assay. JOVE J. Vis. Exp. 2011, 47, 2437. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors B.S and M.Z.H.
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
